InvestorsHub Logo

linhdtu

08/13/14 1:04 PM

#548 RE: DewDiligence #547

In the case of opt in and 50-50 profit sharing, can we trust in the accounting honesty of abbvie ?

After all, profit = sales - costs and costs can manipulated up and down to a certain degree. Ask any home owned business owner , lol.

Being a sceptic on most things, I would prefer that enta to not opt in.

DewDiligence

09/04/14 7:45 PM

#579 RE: DewDiligence #547

ENTA’s decision whether to opt-in for US profit-sharing on the ABT-493/ABT-530 regimen is likely to be made during September, based on comments from today’s Baird webcast. (See #msg-104670740 for background.)

DewDiligence

09/10/14 10:28 AM

#582 RE: DewDiligence #547

ABBV/ENTA start phase-2b trial of pan-genotypic qD 2-DAA regimen of ABT-493+ABT-530:

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-initiation-phase-142200069.html